Experimental assay NAFLD/HO
Experimental assay Human-NAFLD/HO , 4 biopsies from healthy obese patients. Samples for the HO category were obtained in patients undergoing bariatric surgery with a BMI > 30 and subgroups defined by liver histology as follows: HO samples showed a normal liver histology such as the NC samples.
-h692a
-h6758
-h6922
-h7230
[All file here](https://seekbeta.lisym.org/Human-NAFLD/HO/)
Files can be opened and visualised with http://motiontracking.mpi-cbg.de/get/ software
SEEK ID: https://seek.lisym.org/assays/252
Experimental assay
Projects: LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI)
Investigation: Three-dimensional spatially resolved geometrical and functional models of human liver tissue
Study: Generation of 3D spatially resolved geometrical and functional models of human liver tissue
Assay position:
Assay type: Experimental Assay Type
Technology type: Technology Type
Organisms: No organisms
Export PNG
Download
Creators and Submitter
Views: 152
Created: 27th Jan 2022 at 23:14
Last updated: 12th Jun 2024 at 13:53
TagsThis item has not yet been tagged.
Related items
Projects: LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM PALs, LiSyM network, LiSyM-Krebs Partnering, Forschungsnetzwerk LiSyM-Krebs, DEEP-HCC network
Institutions: Zentrum für Informationsdienste und Hochleistungsrechnen (ZIH), Technische Universität Dresden
https://orcid.org/0000-0003-0137-5106
Projects: LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT), LiSyM-Krebs Partnering, Forschungsnetzwerk LiSyM-Krebs, DEEP-HCC network
Institutions: Universitätsklinikum Dresden - Medizinische Klinik I, Bereich Gastroenterologie & Hepatologie, Zentrum für Informationsdienste und Hochleistungsrechnen (ZIH), Technische Universität Dresden
Liver Systems Medicine : striving to develop non-invasive methods for diagnosing and treating NAFLD by combining mathematical modeling and biological research. LiSyM, is a multidisciplinary research network, in which molecular and cell biologists, clinical researchers, pharmacologists and experts in mathematical modeling examine the liver in its entirety. LiSyM research focuses on the metabolic liver disease non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis ...
Projects: LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Pillar IV: Liver Function Diagnostics (LiSyM-LiFuDi), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), The Hedgehog Signalling Pathway (LiSyM-JGMMS), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), LiSyM PALs, Project Management PTJ, LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT)
Web page: https://www.lisym.org/
One of the tasks of the healthy liver is to store fat. Yet, at some stage, too much fat makes the liver sick. One critical time point occurs when a healthy fatty liver becomes inflamed and progresses to steatohepatitis, or NASH. LiSyM-Pillar I will identify what events lead to this transition. Does it occur in all parts of the liver? Which molecules indicate that it is taking place? Can the degeneration be stopped or undone - and if so, how?
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research/zones-of-the-liver
Start date: 1st Jan 2016
We apply multiphoton imaging, 3D digital reconstructions and computational simulations to generate spatially-resolved geometrical and functional models of human liver tissue at different stages of non-alcoholic fatty liver disease (NAFLD).
Histopathological analysis of human biopsies. To quantitatively characterize the transition from simple STEA to eNASH, we stained, imaged and digitally reconstructed human liver tissue in 2D and 3D from biopsies of 25 patients classified into four groups: normal control (NC, n = 6), healthy obese (HO, n = 4), steatosis (STEA, n = 8) and eNASH (n = 7).
